Drug Profile
Research programme: phospholipase A2 inhibitors therapeutics - Ophirex
Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Ophirex
- Class Anti-inflammatories; Antidotes; Antivenins
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Snake venom poisoning
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Snake-venom-poisoning in USA (Parenteral)
- 01 Sep 2017 Ophirex in-licenses sPLA2 inhibitors data from Eli Lilly and Shionogi for Snake venom poisoning
- 29 Aug 2017 Preclinical trials in Snake venom poisoning in USA (Parenteral) before August 2017